Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
5.98
+0.20 (3.46%)
At close: Oct 24, 2025, 4:00 PM EDT
6.05
+0.07 (1.17%)
After-hours: Oct 24, 2025, 7:21 PM EDT
Vir Biotechnology Revenue
Vir Biotechnology had revenue of $1.21M in the quarter ending June 30, 2025, a decrease of -60.52%. This brings the company's revenue in the last twelve months to $19.00M, down -75.91% year-over-year. In the year 2024, Vir Biotechnology had annual revenue of $74.21M, down -13.90%.
Revenue (ttm)
$19.00M
Revenue Growth
-75.91%
P/S Ratio
43.23
Revenue / Employee
$46,569
Employees
408
Market Cap
830.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 74.21M | -11.98M | -13.90% |
| Dec 31, 2023 | 86.18M | -1.53B | -94.67% |
| Dec 31, 2022 | 1.62B | 520.38M | 47.51% |
| Dec 31, 2021 | 1.10B | 1.02B | 1,334.39% |
| Dec 31, 2020 | 76.37M | 68.28M | 843.86% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
VIR News
- 2 days ago - Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025 - Business Wire
- 15 days ago - Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer - Business Wire
- 18 days ago - Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting® 2025 - Business Wire
- 5 weeks ago - Vir Biotechnology, Inc. (VIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference - Business Wire
- 2 months ago - Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results - Business Wire
- 2 months ago - Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta - Business Wire